Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/18/2017 04/19/2017 04/20/2017 04/21/2017 04/24/2017 Date
14.4(c) 14.05(c) 14.45(c) 14.45(c) 14.75(c) Last
513 739 604 796 497 841 294 783 344 981 Volume
+3.97% -2.43% +2.85% 0.00% +2.08% Change
More quotes
Financials ($)
Sales 2017 169 M
EBIT 2017 -26,4 M
Net income 2017 -21,3 M
Debt 2017 -
Yield 2017 -
Sales 2018 202 M
EBIT 2018 -7,22 M
Net income 2018 -8,92 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 3,80x
Capi. / Sales2018 3,17x
Capitalization 641 M
More Financials
Company
Vanda Pharmaceuticals, Inc. engages in the research, development, and commercialization of biopharmaceutical products.It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder.Its product portfolio includes HETLIOZ,... 
More about the company
Surperformance© ratings of Vanda Pharmaceuticals Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on VANDA PHARMACEUTICALS INC.
04/20 VANDA PHARMACEUTICALS : Patent Issued for Metabolites of (1R-Trans)-N-methyl]pro..
04/20 VANDA PHARMACEUTICALS : to Announce First Quarter 2017 Financial Results on May ..
04/13 VANDA PHARMACEUTICALS : to Announce First Quarter 2017 Financial Results on May ..
04/13 VANDA PHARMACEUTICALS : U.S. Patents Awarded to Inventors in Kansas (April 13)
04/06 VANDA PHARMACEUTICALS : and UCSF Announce License Agreement for CFTR Activators ..
03/29 VANDA PHARMACEUTICALS : and UCSF Announce License Agreement for CFTR Activators ..
03/13 VANDA PHARMACEUTICALS INC. (NASDAQ : VNDA) Files An 8-K Departure of Directors o..
03/13 VANDA PHARMACEUTICALS INC. : Change in Directors or Principal Officers (form 8-K..
03/06 VANDA PHARMACEUTICALS INC. : Change in Directors or Principal Officers (form 8-K..
03/06 VANDA PHARMACEUTICALS : Announces Participation at March 2017 Investor Conferenc..
More news
Sector news : Bio Therapeutic Drugs
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
04/18DJACTELION : J&J Lifts Forecast on Actelion Tie-Up--Update
04/18DJJOHNSON & JOHNSON : Lifts Forecast on Actelion Tie-Up
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug -- Up..
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug
More sector news : Bio Therapeutic Drugs
Latest Tweets
04/13Vanda Pharmaceuticals : to Announce First Quarter 2017 Financial Results on M.. 
04/13Steven A. Cohen May Have Met His Match
2
04/12Vanda Pharmaceuticals's buy rating reiterated at Jefferies Group LLC. $21.00 .. 
04/12CIBC Begins Coverage on Vanda Pharmaceuticals Inc. $VNDA  
04/12Vanda Pharmaceuticals initiated by CIBC at outperform. $21.00 PT.  
More tweets
Qtime:15
News from SeekingAlpha
03/22 Vanda Pharmaceuticals (VNDA) Presents At Oppenheimer 27th Annual Healthcare C..
03/08 Vanda Pharmaceuticals (VNDA) Presents At Cowen and Company 37th Annual Health..
03/02 VANDA : Investing For Growth
02/15 Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q4 2016 Results - ..
02/15 Vanda Pharmaceuticals beats by $0.08, misses on revenue
Advertisement
Chart VANDA PHARMACEUTICALS INC.
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | VNDA | US9216591084 | 4-Traders
Full-screen chart
Technical analysis trends VANDA PHARMACEUTI...
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 22,0 $
Spread / Average Target 52%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mihael Hristos Polymeropoulos President, Chief Executive Officer & Director
H. Thomas Watkins Chairman
James Patrick Kelly Chief Financial Officer, Treasurer & Senior VP
Vincent J. Milano Independent Director
Michael F. Cola Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VANDA PHARMACEUTICALS ..-7.52%641
AMGEN, INC.11.58%118 044
CELGENE CORPORATION6.39%95 114
GILEAD SCIENCES, INC.-7.49%86 186
REGENERON PHARMACEUTIC..0.83%39 263
ACTELION LTD26.98%30 294
More Results